Anzeige
Mehr »
Freitag, 16.01.2026 - Börsentäglich über 12.000 News
Diese Goldaktie beschleunigt ihr Explorationsprogramm - Ergebnisse sprengen den Plan
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
DoTrump takes aim at insurance industry, drug prices in unveiling 'The Great Healthcare Plan'
DoFDA tells Sanofi, GSK, AstraZeneca and CSL to include warnings for febrile seizures on flu shot labels
DoFDA chides BeOne, ImmunityBio promo materials in first untitled letters of 2026
DoJPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears
DoAfter succeeding in combo with Darzalex, J&J's Tecvayli shines as solo act
DoHologic sets a screen to block cervical cancer with WNBA's Erica Wheeler
DoBD budgets $110M to expand Nebraska syringe production
MiJPM26: Jazz's $200M voucher sale shows drumbeat of rising prices isn't stopping
MiBayer taps Gabrielle Union-Wade as face of menopause med Lynkuet
MiLenz ups Vizz visibility with DTC campaign starring Sarah Jessica Parker
MiAmneal and VantAI unveil fresh branding to kick off 2026 plans
MiFDA delays decision on Travere's Filspari in key kidney disease indication
MiJPM26: Novo Nordisk CEO reflects on 'curse of a leader' as company looks to reassert GLP-1 footing
DiJPM26: Ionis, bolstered by strong launch of Tryngolza, doubles its sales projection in new indication to $2B
DiJPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases
DiFDA blesses Sentynl and Cyprium's Zycubo as 1st treatment for Menkes disease
DiAbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
MoJPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority
MoCellares to expand cell therapy factory-in-a-box to Europe with new Netherlands facility
MoJPM26: Apellis shares tumble with sales decline for eye disease treatment Syfovre
MoAtara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub
MoBristol Myers Squibb paves way for expansion of Camzyos to adolescent patients
MoAbbVie drops $175M on Ariz. drug-device plant as US investment tour rolls on
09.01.Putting patients first: from buzzword to business imperative
09.01.Athira Pharma roars into the new year with rebrand to LeonaBio